Generic Nexium Availability
Last updated on Oct 9, 2024.
Nexium is a brand name of esomeprazole, approved by the FDA in the following formulation(s):
NEXIUM (esomeprazole magnesium - capsule, delayed rel pellets;oral)
-
Manufacturer: ASTRAZENECA
Approval date: February 20, 2001
Strength(s): EQ 20MG BASE [RLD] [AB], EQ 40MG BASE [RLD] [AB]
NEXIUM (esomeprazole magnesium - for suspension, delayed release;oral)
-
Manufacturer: ASTRAZENECA
Approval date: October 20, 2006
Strength(s): EQ 20MG BASE/PACKET [RLD] [AB], EQ 40MG BASE/PACKET [RLD] [AB] -
Manufacturer: ASTRAZENECA
Approval date: February 27, 2008
Strength(s): EQ 10MG BASE/PACKET [RLD] [AB] -
Manufacturer: ASTRAZENECA
Approval date: December 15, 2011
Strength(s): EQ 2.5MG BASE/PACKET [RLD], EQ 5MG BASE/PACKET [RLD]
Has a generic version of Nexium been approved?
Yes. The following products are equivalent to Nexium:
esomeprazole magnesium capsule, delayed rel pellets;oral
-
Manufacturer: ALKEM LABS LTD
Approval date: October 20, 2017
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: AUROBINDO PHARMA LTD
Approval date: April 21, 2016
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: CISEN
Approval date: September 22, 2020
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: CSPC OUYI
Approval date: October 2, 2020
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: DR REDDYS
Approval date: September 25, 2015
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: ETHYPHARM
Approval date: March 31, 2021
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: GRANULES
Approval date: October 18, 2023
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: GRAVITI PHARMS
Approval date: March 19, 2021
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: GUANGZHOU NOVAKEN
Approval date: November 18, 2020
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: HETERO LABS LTD III
Approval date: June 2, 2020
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: INDCHEMIE HEALTH
Approval date: February 26, 2021
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: IVAX SUB TEVA PHARMS
Approval date: January 26, 2015
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: LANNETT CO INC
Approval date: September 1, 2017
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: MYLAN
Approval date: August 2, 2015
Strength(s): EQ 20MG BASE [AB] -
Manufacturer: MYLAN
Approval date: August 3, 2015
Strength(s): EQ 40MG BASE [AB] -
Manufacturer: PRINSTON INC
Approval date: March 28, 2023
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: SUN PHARM
Approval date: April 30, 2018
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: ZHEJIANG YONGTAI
Approval date: December 27, 2023
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB] -
Manufacturer: ZYDUS PHARMS
Approval date: May 22, 2019
Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB]
esomeprazole magnesium for suspension, delayed release;oral
-
Manufacturer: CIPLA
Approval date: March 23, 2020
Strength(s): EQ 10MG BASE/PACKET [AB], EQ 20MG BASE/PACKET [AB], EQ 40MG BASE/PACKET [AB] -
Manufacturer: ZYDUS PHARMS
Approval date: June 7, 2023
Strength(s): EQ 20MG BASE/PACKET [AB], EQ 40MG BASE/PACKET [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexium. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Nexium (esomeprazole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (210)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: proton pump inhibitors
- Breastfeeding
- En español
Patient resources
- Nexium drug information
- Nexium (Esomeprazole Delayed-Release Capsules)
- Nexium (Esomeprazole Powder for Suspension)
Other brands
Professional resources
Other formulations
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.